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Introduction
The conventional regimens for the treatment
of pulmonary tuberculosis are less effective in
patients with multiple drug-resistant organisms
than in those harbouring fully sensitive strains1.
The currently available alternative regimens for
the treatment of patients with multiple drug
resistance offer limited success besides being
more toxic, more expensive and often resulting in
the development of acquired resistance to the
other drugs used2. For the treatment of patients
with drug-resistant bacilli, several new classes of
antituberculosis agents have been studied in vitro
and in vivo. These include the aminoglycosides
such as Amikacin and Capreomycin, long-acting
Rifamycins (e.g. Rifapentine and Rifabutin), the
4-fluoroquinolones and combinations of b- lactum
agents with b- lactamase inhibitors3,4.
We report here the in vitro activity of an
aminoglycoside, Capreomycin and a
fluoroquinolone, Ciprofloxacin on south Indian
isolates of M. tuberculosis, ensitive and resistant
to Streptomycin, Isoniazid and Rifampicin, the
drugs frequently used in short course regimens.
Material and Methods
Cultures : A total of 107 M. tuberculosis  strains
isolated from as many patients were tested. These
comprised 53 isolates sensitive to Streptomycin
(S), Isoniazid (H) and Rifampicin (R), and 54
resistant to SHR or HR. The standard sensitive
strain M. tuberculosis H37Rv was tested on six
occasions.
Drug concentrations :Capreomycin and
Ciprofloxacin were dissolved in water and
incorporated in Lowenstein-Jensen (L-J) medium
o give pre-inpissation concentrations of 1, 2, 4,
8, 16, 32 and 64 mcg/ml.
Se sitivity testing: A standard bacterial
suspension (4 mg/ml) of the cultures, which were
given code numbers to conceal their identity, was
inoculated with a 3mm loop on to 2 drug-free
slopes and one slope each with the different
c ncentrations of the drugs. All slopes were
incubated at 37°C and at the end of 4 weeks of
incubation, the minimal inhibitory concentration
(MIC) was determined using the 20-colony end
point5.
Results
MIC for Capreomycin: The standard strain,
M. tuberculosis H37Rv, tested on 6 different
occasions, gavean MIC of 16 mcg/ml on 2
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occasions and an MIC of 32 on 4 occasions for
Capreomycin, the geometric mean MIC being
25.4 mcg/ml (Table 1).
The distributions of MICs for Capreomycin
for the strains from patients showed that the
percentages of sensitive and resistant strains with
MICs of 16, 32 and 64 were fairly similar.
However, 3(6%) of 53 SHR sensitive strains had
an MIC of > 54 as against 8 (15%) of 54 SHR/
HR resistant strains, the difference not being
statistically significant. The geometric mean
MICs for SHR sensitive and SHR/HR resistant
strains were 36.5 and 41.4 mcg/ml respectively,
the overall mean being 38.9 mcg/ml.
MIC for Ciprofloxacin: The MIC of Ciprofloxacin
for M. tuberculosis H37Rv was 2 mcg/ml on all 6
occasions tested (Table 2). The percentage
distributions of the MICs with the different
categories of strains were very similar, there
being no difference between sensitive and
resistant cultures, and the geometric mean MICs
being 3.7 and 3.8 mcg/ml, respectively. These
observations suggest the probability of non-
existence of cross-resistancebetween
Ciprofloxacin and Streptomycin, Isonazid or
Rifampicin.
Discussion
Although primary resistance to Rifampicin in
most countries is rare at present, it may become
more prevalent because of the increasing use of
Rifampicin containing regimens4. A study from
Gujarat has reported an alarming increase in
Table 1 Minimal inhibitory concentrations of Capreomycin against south Indian isolates of M. tuberculosis
Category of
strain
No. tested MIC* of Capreomycin (mcg/ml)
16 32 64 >64
No. % No. % No. % No. %
Standard
(H37Rv) 6 2 – ** 4 – 6 – 0 –
SHR Sens. 53 6 11 34 64 10 19 3 6
SHR/HR Res. 54 6 11 30 56 10 19 8 15
Total patients 107 12 11 64 60 20 19 11 10
* No strain had an MIC of less than 16.
** A dash(-) indicates that no percentages is presented because the total is less than 10.
Table 2 Minimal inhibitory concentrations of Ciprofloxacin against south Indian isolates of M. tubercul sis
No. tested MIC* of Ciprofloxacin (mcg/ml)
<1 2 4 8
No. % No. % No. % No. %
Standard
(H37Rv) 6 0 –– 6 –** 0 – 0
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acquired Rifampicin resistance from, 2.8% in
1980 to 37.3% in 1986, 95% of the patients being
 resistant to Streptomycin, Isoniazid or both6. In
view of the possibility of an increase in
Rifampicin resistance among tuberculosis
patient;. there is a felt need for investigations into
newer anti-tuberculosis drugs4.
A recent study done at this Centre on the
activity of Rifapentine and Rifabutin on
Rifampicin resistant strains revealed complete
cross resistance between Rifampicinand
Rifapentine while a partial cross resistance (78%)
was observed between Rifampicin and Rifabutin
in vitro7.
Although Amikacin has been shown to be
effective against M. avium-intracellullare complex,
Allen and others have concluded that the activity
of this drug against M. tuberculosis is very low
and, as such, it might not be effective in the
treatment of disease caused by M. tuberculosis.
No cross-resistance has been reported
between Streptomycin and Capreomycin8,9,10.
Very little information is available on the activity
of Capreomycin on Rifampicin resistant strains.
Our study has shown that 6% of SHR susceptible
strains as against 1.5% of SHR/HR resistant
strains had an MIC of >64 for Capreomycin. The
strains with MIC of >64 could probably be
considered as resistant to Capreomycin, adopting
the same criteria as for Kanamycin resistances.
This observation suggests a role for Capreomycin
in the treat   ment of patients with multiple drug-
resistant organisms.
Interest in quinolones has grown during the
last decade owing to the development of
fluorinatedcarboxylic acid derivatives such as
Norfloxacin,Perfloxacin, Ofloxacin, Enoxacin
and Ciprofloxacin. These derivatives possess a
broad spectrum of activity against drug resistant
bacteria in general, including drug-resistant
mycobacteria11,12. Ciprofloxacin is one of the
quinolones with the lowest MIC against
M. tuberculosis13 and is more active than
Norfloxacin and Enoxacin12,14. No cross-resistance
has beern eported between the fluoroquinolones
and other anti-TB drugs1.
The present study on 107 strains showed no
significant difference in the activity of
Ciprofloxacin between SHR sensitive and
resistant strains, the mean MICs being 3.7 and 3.8
mcg/ml, respectively. This value agrees well with
other reports on the activity of Ciprofloxacin in
L-J medium14,15,16.                      The peak serumconcentration
of Ciprofloxacin with conventional oral doses of
500-750 mg ranges between 2 and 4 ug/ml. It may
be observed that the mean MIC of Ciprofloxacin
is slightly below the maximum peak serum level.
Indeed, several authors have reported that the
MIC of fluoroquinolones is only slightly below
the peak blood levels attainable with therapeutic
dos s of the drug 1,17,18.
However, in pulmonary tissue the drug may
attain levels in excess of those in serum which
may be adequate to inhibit growth of strains with
resistance to one or more primary drugs7. Fo
example, Ciprofloxacin levels obtained in the
prostatic tissue are 2-14 times greater than serum
levels19. In the light of the encouraging in vitro
finding, it appears that Ciprofloxacin might be a
useful drug in the treatment of multi-drug
resistant tuberculosis, if used in judicious
combination with other drugs.
However, the importance of these drugs in the
hemotherapy of tuberculosis including its role
in the treatment of patients with multi-drug
resistance can be assessed only after well-
pl ned controlled clinical trials.
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